-
Mashup Score: 4Honoring Stephen A. Harrison, MD, FAASLD: Pioneer who ‘propelled field of MASH forward’ - 13 day(s) ago
Col. Stephen A. Harrison, MD, FAASLD, a key leader in the field of hepatology who dedicated his life to caring for patients and developing treatments for liver disease, died on April 23. Harrison founded and chaired Pinnacle Clinical Research in San Antonio and was a pioneer in liver disease research, particularly in pursuit of treatment options for metabolic dysfunction-associated steatotic
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4Honoring Stephen A. Harrison, MD, FAASLD: Pioneer who ‘propelled field of MASH forward’ - 17 day(s) ago
Col. Stephen A. Harrison, MD, FAASLD, a key leader in the field of hepatology who dedicated his life to caring for patients and developing treatments for liver disease, died on April 23. Harrison founded and chaired Pinnacle Clinical Research in San Antonio and was a pioneer in liver disease research, particularly in pursuit of treatment options for metabolic dysfunction-associated steatotic
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
Please join us as we honor Stephen A. Harrison, MD, FAASLD: A pioneer who ‘propelled field of #MASH forward,’ a colleague and a friend. ⬇️⬇️ https://t.co/qnC3s77F9n
-
-
Mashup Score: 41
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic liver disease worldwide. In this review, Tincopa et al. highlight challenges and potential solutions in drug development for MASH. They cover current advances in pharmacotherapy for MASH, presenting promising data from several agents in the pipeline.
Source: www.cell.comCategories: General Medicine News, General HCPsTweet-
RT @DanielJDrucker: In 5 years, what will the preferred therapies for #MASH look like? @DrLoomba @Cell_Metabolism https://t.co/pwEnB2Th9H
-
-
Mashup Score: 5MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH - 3 month(s) ago
Background Dynamic changes in non-invasive tests, such as changes in alanine aminotransferase (ALT) and MRI proton-density-fat-fraction (MRI-PDFF), may help to detect metabolic dysfunction-associated steatohepatitis (MASH) resolution, but a combination of non-invasive tests may be more accurate than either alone. We developed a novel non-invasive score, the MASH Resolution Index, to detect the histological resolution of MASH. Methods This study included a derivation cohort of 95 well-characterised adult participants (67% female) with biopsy-confirmed MASH who underwent contemporaneous laboratory testing, MRI-PDFF and liver biopsy at two time points. The primary objective was to develop a non-invasive score to detect MASH resolution with no worsening of fibrosis. The most predictive logistic regression model was selected based on the highest area under the receiver operating curve (AUC), and the lowest Akaike information criterion and Bayesian information criterion. The model was then e
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
RT @DanielJDrucker: The quest to avoid the requirement for serial liver biopsies #MASH @DrLoomba @Gut_BMJ https://t.co/4G93XUpapE
-
-
Mashup Score: 1
HU6 could be a promising pharmacological agent for treating patients with obesity and NAFLD and its metabolic complications.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet-
New research - Noureddin et al - Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial https://t.co/Z2pHkCazR2 #LiverTwitter #NASH #MASH @NoureddinMD https://t.co/q5tuyS7RcM
-
-
Mashup Score: 2
HU6 could be a promising pharmacological agent for treating patients with obesity and NAFLD and its metabolic complications.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet-
New research - Noureddin et al - Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial https://t.co/Z2pHkCb7GA #LiverTwitter #NASH #MASH @NourredinMD https://t.co/rryNzriYX6
-
-
Mashup Score: 0Efruxifermin in non-alcoholic steatohepatitis - 8 month(s) ago
Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the commonest causes of liver-related mortality and morbidity, with a predicted global prevalence of 30%.1 This finding has fuelled extensive therapeutic research; however, there are no currently licensed therapies for NAFLD, with weight loss and lifestyle interventions as the mainstay of treatment.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet-
Linked Comment - Sara Mahgoub & Phil Newsome - Efruxifermin in non-alcoholic steatohepatitis https://t.co/XwqA1W4hMX #LiverTwitter #NASH #MASH @phil_newsome7
-
-
Mashup Score: 8NASH drug treatment development: challenges and lessons - 9 month(s) ago
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity. NAFLD increases the risk of developing cardiovascular disease, chronic kidney disease, and certain extrahepatic cancers. There is currently no licensed pharmacotherapy for NAFLD, despite numerous clinical trials in the past two decades. Currently, the reason so few drugs have been successful in the treatment of NAFLD in a trial setting is not fully understood.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet-
New Review online — NASH drug treatment development: challenges and lessons, by Tilg, Byrne and Targher A wide range of mechanisms are being studied; ideal #NASH candidates should be safe and hepatoprotective+cardioprotective https://t.co/QiwTPypNUf #MASLD #MASH #LiverTwitter https://t.co/wKnEORh4gV
-
-
Mashup Score: 1Magnetic resonance elastography bests other diagnostic tests for identifying at-risk NASH - 11 month(s) ago
WASHINGTON — Magnetic resonance elastography was among the most accurate screening test to identify patients with at-risk nonalcoholic steatohepatitis, according to study results presented at The Liver Meeting. “This study is setting the stage for how these tests can be used to identify who needs to be treated without needing a liver biopsy,” Rohit Loomba, MD, MHSc, director of
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
RT @Resoundant: Great summary in @HealioGastro on how MRE is helping manage at-risk #MASLD and #MASH patients https://t.co/yTC1hP5zSq
-
-
Mashup Score: 3
Kiniksa Pharmaceuticals.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
#Mavrilimumab in patients with #severe #COVID- #19 #pneumonia and #systemic #hyperinflammation ( #MASH- #COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial https://t.co/NSoGmwhTXn https://t.co/gEpXXSZNmb
-
Please join us as we honor Stephen A. Harrison, MD, FAASLD: A pioneer who ‘propelled field of #MASH forward,’ a colleague and a friend. ⬇️⬇️ https://t.co/qnC3s77F9n